Explore daily insights on
Zealand Pharma jumps 12% on May 7 after Phase 3 obesity trial success with above-average volume
- Zealand Pharma (ZEAL.CO) closed at DKK 353.50 on May 7, up 12.2% from its prior close of DKK 315.20, on volume of 684,477 shares — roughly 1.5x its recent daily run-rate
- The move follows Boehringer Ingelheim's Phase 3 SYNCHRONIZE-1 trial for survodutide (licensed from Zealand), which showed 'Wegovy-like' weight loss and potential muscle mass preservation
- The stock has risen 26% since April 6 (DKK 276.90) but remains 35.3% below its 52-week high of DKK 545.80, suggesting the market is still pricing significant execution risk
Supporting datasets
Supporting queries
To surface this insight, Baselight ran 8 queries across its structured data. Each one is reproducible — open it, read the SQL, and rerun it yourself.
Conclusion
daily_prices: ZEAL.CO close DKK 353.50 on May 7 vs prev close DKK 315.20, pct_chg +12.2%, volume 684,477; 52w high DKK 545.80, 52w low DKK 234.90. News: 'Boehringer dual-acting obesity shot hits mark in Phase 3 trial' (BioPharma Dive, Apr 28); 'Assessing Zealand Pharma Valuation After Positive Survodutide Phase 3 Obesity Trial Results' (Simply Wall St., Apr 29).